Ironwood Pharmaceuticals, Inc. is a biotechnology company focused on the development and commercialization of therapies for gastrointestinal and rare diseases. Its primary commercial product is LINZESS (linaclotide), a guanylate cyclase type C agonist indicated for irritable bowel syndrome with constipation, chronic idiopathic constipation, and functional constipation in the United States. The drug is marketed as CONSTELLA in Canada and certain European countries. The company is advancing apraglutide, a long-acting synthetic peptide analog of glucagon-like peptide-2, for the treatment of short bowel syndrome with intestinal failure. Ironwood holds strategic partnerships with AbbVie for the U.S. and most international markets, AstraZeneca for China, and Astellas Pharma for Japan. The company was incorporated in 1998 as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in 2008. It acquired VectivBio Holding AG in 2023 to expand its pipeline in rare diseases.

Summarised from the company's own disclosures, fiscal year ended Feb 2026

Industry Biotechnology Homepage ironwoodpharma.com
Sector Healthcare IR page investor.ironwoodpharma.com/home/default.aspx
Tags
gastrointestinal diseases, rare diseases, constipation, irritable bowel syndrome, short bowel syndrome, peptide therapeutics, clinical trials, drug development, LINZESS, linaclotide, CONSTELLA, apraglutide, VectivBio, AbbVie, AstraZeneca, Astellas Pharma, STARS, STARS-2
Press page —

Metrics

Valuation  
Market cap $ 796.299M
Market cap (USD) $ 796.299M
P/E 5.23
PEG —
P/BV -8.19
P/S 1.99
P/OCF 3.88
P/FCF 6.27
Dividend yield —
Turnover / mcap —
Returns  
ROE -9.2%
ROI 7.4%
ROIC 15.3%
Profit margin 8.1%
Growth  
Revenue growing No
Profits growing Yes
Revenue up 3y No
Revenue up 5y No
Earnings growth 3y (net profit CAGR) -48.4%
Quality  
Profitable Yes
Margin expanding Yes
Buying back stock No
Diluting (TTM) Yes
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 35
Quality score 16.7%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009 FY 2008
Revenue 296.151M 351.41M 442.735M 410.596M 413.753M 389.523M 428.413M 346.639M 298.276M 273.957M 149.555M 76.436M 22.881M 150.245M 65.871M 43.857M 36.102M 22.216M
Net profit 24.017M 880K -1.002B 175.065M 528.448M 106.2M 21.505M -282.368M -116.937M -81.708M -142.669M -189.618M -272.812M -72.624M -64.852M -51.86M -71.185M -53.874M
Free cash flow 127.01M 103.407M 183.154M 273.627M 261.63M 166.994M 3.536M -79.503M -103.774M -29.639M -110.976M -159.106M -282.947M -83.612M -84.919M -85.119M -8.043M -51.129M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009 FY 2008
Share price 3.37 4.43 11.44 12.39 11.66 11.39 13.31 10.36 14.99 15.29 11.59 15.32 11.61 11.08 11.94 11.25 — —
Price performance 12m -0.24 -0.61 -0.08 0.06 0.02 -0.14 0.28 -0.31 -0.02 0.32 -0.24 0.32 0.05 -0.07 0.06 — — —

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) 933,000 3.19M 21M 11.3M 122M 114M 115M 129M 81.9M 46.7M
↳ YoY growth -67.6% +241.9% +558.0% -46.3% +984.8% -6.8% +1.2% +11.8% -36.6% -42.9%
↳ 5y CAGR +66.0% +47.5% +110.1% +307.8% +111.6% +161.5% +105.0% +43.8% +48.7% -17.5%
Lease liabilities (USD) — — 94.9M 23.2M 23.4M 21.6M 19.7M 17.7M 15.5M 13.1M
Cash and deposits (USD) 54M 126M 173M 177M 363M 620M 656M 92.2M 88.6M 215M
Intangible assets (USD) 166M 160M — — — — — 3.68M 2.86M 2.04M
Right-of-use assets (USD) — — 88.3M 17.7M 16.6M 15.4M 14M 12.6M 11M 9.34M
Cash flow detail
Operating cash flow (USD) -25.4M -99.6M -70.9M 10.7M 169M 262M 274M 183M 104M 127M
Purchases of property, plant and equipment (USD) -4.21M -4.21M -8.62M -7.19M -1.84M -265,000 -136,000 -273,000 -142,000 -34,000
Change in receivables (cash effect) (USD) -10.3M -17.3M 1.21M -68.9M 4.09M 7.71M 7.99M 924,000 47.2M 35.1M
Change in inventories (cash effect) (USD) — 346,000 -806,000 — 648,000 — — — — —
Change in payables (cash effect) (USD) 19.7M -6.84M 8.06M -32.7M -7.52M -2.64M -8.12M 12.4M -20.2M 6.2M
Share buybacks (cash effect) (USD) — — — — — -24.1M -126M — — —
Interest paid (cash effect) (USD) -24.5M -20.4M -18.2M -17.6M -7.22M -7.22M -5.75M -13.6M -32.6M -30.3M
Income taxes paid (cash effect) (USD) — — — — -1.85M -3.45M -4.62M -9.95M -8.41M -3.54M
Share-based compensation (USD) 29.2M 33.8M 44M 31.3M 31.2M 22.3M 27M 32M 29.9M 17.3M
Operating cash flow before change in receivables (USD) -15.1M -82.3M -72.1M 79.6M 165M 254M 266M 183M 56.3M 91.9M
Free cash flow (OCF - PPE - intangibles) (USD) -29.6M -104M -79.5M 3.54M 167M 262M 274M 183M 103M 127M
Income detail
Research and development expense (USD) 139M 148M 167M 115M 88.1M 70.4M 44.3M 116M 111M 95.1M
↳ 5y CAGR +10.1% +5.5% +10.2% +2.5% -4.1% -12.8% -21.5% -7.0% -0.6% +1.6%
Total comprehensive income (USD) -81.6M -117M -282M 21.5M 106M 528M 175M -1.01B 4.83M 22M
Comprehensive income to owners (USD) -81.6M -117M -282M 21.5M 106M 528M 175M -1.01B 4.83M 22M
Reported Feb 22, 2017 Feb 22, 2018 Oct 31, 2019 Feb 13, 2020 Feb 17, 2021 Feb 18, 2022 Feb 16, 2023 Feb 16, 2024 Mar 31, 2025 Feb 26, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

November 5, 2026

– Raises full-year 2026 LINZESS® (linaclotide) U.S. net sales guidance to $1.20 - $1.25 billion, representing greater than 35% increase year-over-year; Raises total 2026 revenue guidance to $485 - $510 million and adjusted EBITDA guidance to greater than $350 million –

– Q3 2026 LINZESS U.S. net sales of $325 million; $880 million year-to-date U.S. net sales exceeds full-year 2025 U.S. net sales –

– Total revenue of $133 million, GAAP net income of $60 million and record adjusted EBITDA of $98 million in Q3 2026 –

– STARS-2 confirmatory Phase 3 trial of apraglutide in short bowel syndrome with intestinal failure (SBS-IF) is ongoing; Planned U.S. and global site expansion on track –

BOSTON--(BUSINESS WIRE)-- Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a biotechnology company developing and commercializing life‑changing therapies for people living with gastrointestinal (GI) and rare diseases, today reported its third quarter 2026 results and recent business performance update.

“Ironwood delivered a third consecutive strong quarter as we continue focused execution of our three strategic priorities: maximize LINZESS, advance apraglutide and deliver sustained profits and cash flows. We believe LINZESS is on its way to returning to blockbuster status for 2026 with year-to-date U.S. net sales already surpassing total 2025 U.S. net sales, primarily driven by improved net price and mid-single-digit prescription demand growth. This gives us confidence to increase full-year 2026 financial guidance for the second consecutive quarter,” said Ironwood Chief Executive Officer Tom McCourt.

“In addition to driving strong financial performance, we are ramping up the STARS-2 confirmatory Phase 3 trial of apraglutide in people living with short bowel syndrome with intestinal failure. As we continue to add trial sites in the U.S., all of the planned clinical trial applications have been submitted to international health authorities and are now under review or already approved. Our current focus is on activating sites as quickly as possible to accelerate the trial as we work toward the goal of bringing apraglutide to patients,” McCourt continued.

Third Quarter 2026 Financial Highlights1

(in thousands, except for per share amounts) Q3 2026 Q3 2025
Total revenue $ 133,040 $ 122,060
Total costs and expenses 39,906 46,576
GAAP net income 59,838 40,080
GAAP net income – per share basic 0.36 0.25
GAAP net income – per share diluted 0.36 0.23
Adjusted EBITDA1 97,925 81,811
Non-GAAP net income 60,045 41,933
Non-GAAP net income per share – basic 0.36 0.26
Non-GAAP net income per share – diluted 0.36 0.24
1 Refer to the Reconciliation of GAAP Results to Non-GAAP Financial Measures table and to the Reconciliation of GAAP Net Income to Adjusted EBITDA table at the end of this press release. Refer to Non-GAAP Financial Measures for additional information.

Third Quarter Corporate Highlights

U.S. LINZESS

  • Prescription Demand: Total LINZESS prescription demand in the third quarter of 2026 was 63.4 million LINZESS capsules, a 4.9% increase compared to the third quarter of 2025, per IQVIA.
  • U.S. Brand Collaboration: LINZESS U.S. net sales are provided to Ironwood by its U.S. partner, AbbVie Inc. (“AbbVie”). LINZESS U.S. net sales were $324.9 million in the third quarter of 2026, a 3.2% increase compared to $314.9 million in the third quarter of 2025. Ironwood and AbbVie share equally in U.S. brand collaboration profits.
    • Q3 2026 LINZESS U.S. net sales growth year-over-year was driven by 4.9% demand growth and low single-digit net price decline due to unfavorable gross-to-net rebate reserves in the third quarter of 2026 relative to 2025.
    • LINZESS commercial margin was 79.8% in the third quarter of 2026, compared to 75.9% in the third quarter of 2025. See the U.S. LINZESS Full Brand Collaboration table at the end of this press release.
    • Net profit for the LINZESS U.S. brand collaboration, net of commercial and research and development (“R&D”) expenses, was $255.9 million in the third quarter of 2026, a 9.8% increase compared to $233.1 million in the third quarter of 2025. See the U.S. LINZESS Full Brand Collaboration table at the end of this press release.
  • Collaboration Revenue to Ironwood: Ironwood recorded $129.9 million in collaboration revenue in the third quarter of 2026 related to sales of LINZESS in the U.S., an 8.6% increase compared to $119.6 million for the third quarter of 2025. See the U.S. LINZESS Commercial Collaboration table at the end of the press release.

Apraglutide

  • Apraglutide is an investigational once-weekly, long-acting synthetic glucagon-like peptide-2 (“GLP-2”) analog with the potential to treat a range of rare GI diseases in which GLP-2 can play a central role in addressing disease pathophysiology. Based on the positive results generated from the STARS Phase 3 clinical trial, Ironwood believes apraglutide has the potential to advance the standard of care for adult patients with short bowel syndrome (“SBS”) who are dependent on parenteral support (“PS”).
  • STARS-2 is a global, 24-week, randomized, double-blind, placebo-controlled confirmatory Phase 3 clinical trial evaluating the efficacy and safety of apraglutide in adults with SBS-IF. The primary endpoint is the relative change from baseline in actual weekly PS volume at week 24. The planned activation of more than 100 sites in 22 countries is on track. Subject to the results of the STARS-2 clinical trial, Ironwood plans to file for regulatory approval in 2029 and aims to identify opportunities to accelerate the development program.

Corporate Updates

  • In October, Ironwood’s Chief Commercial Officer Tammi Gaskins was appointed Chief Executive Officer and a member of the Board of Directors, effective January 1, 2027. On that date, Chief Executive Officer Tom McCourt will retire from his current role and will remain a member of the Board of Directors.

Third Quarter 2026 Financial Results

  • Total Revenue. Total revenue in the third quarter of 2026 was $133.0 million, compared to $122.1 million in the third quarter of 2025.
    • Total revenue in the third quarter of 2026 consisted of $129.9 million associated with Ironwood’s share of the net profits from sales of LINZESS in the U.S., and $3.1 million in royalties and other revenue. Total revenue in the third quarter of 2025 consisted of $119.6 million associated with Ironwood’s share of the net profits from sales of LINZESS in the U.S., and $2.5 million in royalties and other revenue.
  • Total Costs and Expenses. Total costs and expenses in the third quarter of 2026 were $39.9 million, compared to $46.6 million in the third quarter of 2025.
    • Total costs and expenses in the third quarter of 2026 consisted of $28.3 million in R&D expenses and $11.6 million in selling, general and administrative (“SG&A”) expenses. Total costs and expenses in the third quarter of 2025 consisted of $22.5 million in R&D expenses, $21.9 million in SG&A expenses, and $2.2 million in restructuring expenses.
  • Interest Expense. Interest expense was $6.2 million in the third quarter of 2026, in connection with Ironwood’s revolving credit facility. Interest expense was $8.4 million in the third quarter of 2025 in connection with Ironwood’s convertible senior notes and revolving credit facility.
  • Interest and Investment Income. Interest and investment income was $0.6 million in the third quarter of 2026 and $0.9 million in the third quarter of 2025.
  • Other. Other income was insignificant in the third quarter of 2026 and in the third quarter of 2025 and pertained to a gain recorded for pension-related activities.
  • Income Tax Expense. Ironwood recorded $27.8 million of income tax expense in the third quarter of 2026, the majority of which was non-cash, as Ironwood continues to utilize net operating losses and tax credits to offset taxable income for federal purposes and in certain states. Ironwood recorded $27.9 million of income tax expense in the third quarter of 2025, the majority of which was non-cash, as Ironwood continued to utilize net operating losses to offset taxable income for federal purposes and in many states.
  • GAAP Net Income. GAAP net income was $59.8 million, or $0.36 per share (basic and diluted) in the third quarter of 2026, compared to GAAP net income of $40.1 million, or $0.25 per share (basic) and $0.23 per share (diluted) in the third quarter of 2025.
  • Non-GAAP Net Income. Non-GAAP net income was $60.0 million, or $0.36 per share (basic and diluted), in the third quarter of 2026, compared to non-GAAP net income of $41.9 million, or $0.26 per share (basic) and $0.24 per share (diluted), in the third quarter of 2025.
    • Non-GAAP net income excludes the impact of amortization of acquired intangible assets and net restructuring expenses, all net of tax effect. See Non-GAAP Financial Measures below.
  • Adjusted EBITDA. Adjusted EBITDA was $97.9 million in the third quarter of 2026, compared to $81.8 million in the third quarter of 2025.
    • Adjusted EBITDA is calculated by subtracting stock-based compensation, net restructuring expenses, net interest expense, income taxes, depreciation and amortization from GAAP net income. See Non-GAAP Financial Measures below.
  • Cash Flow Highlights. Ironwood ended the third quarter of 2026 with $86.4 million of cash and cash equivalents, compared to $215.5 million of cash and cash equivalents at the end of 2025.
    • Ironwood repaid $60.0 million on the revolving credit facility during the third quarter of 2026, reducing the outstanding principal balance to $325.0 million as of September 30, 2026, with $225.0 million of remaining borrowing capacity available under the facility.
    • Ironwood generated $67.4 million in cash from operations in the third quarter of 2026, compared to $47.6 million in cash from operations in the third quarter of 2025.
    • Ironwood had $132.7 million in accounts receivable as of September 30, 2026, primarily related to the third quarter 2026 collaboration revenues.
  • Ironwood 2026 Financial Guidance. Ironwood is raising its 2026 financial guidance and now expects:
Prior 2026 Guidance(August 2026) Updated 2026 Guidance(November 2026)
U.S. LINZESS Net Sales $1.15 - $1.20 billionDriven by improved net price and mid-single digit percentage demand growth $1.20 - $1.25 billionDriven by improved net price and mid-single digit percentage demand growth
Total Revenue1 $460 - $485 million $485 - $510 million
Adjusted EBITDA2 >$310 million >$350 million
1 Ironwood’s U.S. collaborative arrangements revenue includes reimbursement from AbbVie for a portion of Ironwood’s commercial expenses related to sales of LINZESS in the U.S.
2 Adjusted EBITDA is calculated by subtracting stock-based compensation, net restructuring expenses, net interest expense, income taxes, depreciation and amortization from GAAP net income. For purposes of this guidance, we have assumed that Ironwood will not incur material expenses related to business development activities in 2026. Ironwood does not provide guidance on GAAP net income or a reconciliation of expected adjusted EBITDA to expected GAAP net income because, without unreasonable efforts, it is unable to predict with reasonable certainty the non-GAAP adjustments used to calculate adjusted EBITDA. These adjustments are uncertain, depend on various factors and could have a material impact on GAAP net income for the guidance period. Management believes this non-GAAP information is useful for investors, taken in conjunction with Ironwood’s GAAP financial statements, because it provides greater transparency and period-over-period comparability with respect to Ironwood’s operating performance. These measures are also used by management to assess the performance of the business. Investors should consider these non-GAAP measures only as a supplement to, not as a substitute for or as superior to, measures of financial performance prepared in accordance with GAAP. In addition, these non-GAAP financial measures are unlikely to be comparable with non-GAAP information provided by other companies.

Non-GAAP Financial Measures

Ironwood presents non-GAAP net income and non-GAAP net income per share to exclude amortization of acquired intangible assets and net restructuring expenses, all net of tax effect. Non-GAAP adjustments are further detailed below:

  • Amortization of acquired intangible assets are non-cash expenses arising in connection with the acquisition of VectivBio and are considered to be non-recurring.
  • Restructuring expenses are considered to be a non-recurring event as they are associated with distinct operational decisions. Restructuring expenses include costs associated with exit and disposal activities.

Ironwood also presents adjusted EBITDA, a non-GAAP measure, as well as guidance on adjusted EBITDA. Adjusted EBITDA is calculated by subtracting stock-based compensation, net restructuring expenses, net interest expense, income taxes, depreciation and amortization from GAAP net income. The adjustments are made on a similar basis as described above related to non-GAAP net income, as applicable.

Management believes this non-GAAP information is useful for investors, taken in conjunction with Ironwood’s GAAP financial statements, because it provides greater transparency and period-over-period comparability with respect to Ironwood’s operating performance. These measures are also used by management to assess the performance of the business. Investors should consider these non-GAAP measures only as a supplement to, not as a substitute for or as superior to, measures of financial performance prepared in accordance with GAAP. In addition, these non-GAAP financial measures are unlikely to be comparable with non-GAAP information provided by other companies. For a reconciliation of non-GAAP net income and non-GAAP net income per share to GAAP net income and GAAP net income per share, respectively, and for a reconciliation of adjusted EBITDA to GAAP net income, please refer to the tables at the end of this press release.

Ironwood does not provide guidance on GAAP net income or a reconciliation of expected adjusted EBITDA to expected GAAP net income because, without unreasonable efforts, it is unable to predict with reasonable certainty the non-GAAP adjustments used to calculate adjusted EBITDA. These adjustments are uncertain, depend on various factors and could have a material impact on GAAP net income for the guidance period.

Conference Call Information

Ironwood will host a conference call and webcast at 8:30 a.m. Eastern Time on Thursday, November 5th, 2026, to discuss its third quarter results and recent business activities. Individuals interested in participating in the call should dial (833) 461-5787 (U.S.) or (585) 542-9983 (international) using conference ID number and event passcode 496523279. To access the webcast, please visit the Investors section of Ironwood’s website at www.ironwoodpharma.com . The call will be available for replay via telephone starting Thursday, November 5th, 2026, at approximately 11:30 a.m. Eastern Time, running through 11:59 p.m. Eastern Time on Thursday, November 19th, 2026. To listen to the replay, dial (833) 309-1852 (U.S.) or (929) 828-5978 (international) using conference ID number 496523279. Following the call, a replay of the webcast will be available on the Investors & Media section of the company’s website at: Ironwood Pharmaceuticals, Inc. - Events & Presentations . The archived webcast will be available on Ironwood’s website for 1 year.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals (Nasdaq: IRWD) is a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI) and rare diseases. Ironwood is advancing apraglutide, a next-generation, long-acting synthetic GLP-2 analog being developed for short bowel syndrome patients who are dependent on parenteral support. In addition, Ironwood has been a pioneer in the development of LINZESS® (linaclotide), the U.S. branded prescription market leader for the treatment of irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC). Building upon our history of innovation, we keep patients at the heart of our R&D and commercialization efforts to reduce the burden of diseases and address significant unmet needs.

Founded in 1998, Ironwood Pharmaceuticals is headquartered in Boston, Massachusetts, with a site in Basel, Switzerland.

We routinely post information that may be important to investors on our website at www.ironwoodpharma.com . In addition, follow us on X and on LinkedIn .

About LINZESS (Linaclotide)

LINZESS® is the #1 prescribed brand in the U.S. for the treatment of patients with irritable bowel syndrome with constipation (“IBS-C”) or chronic idiopathic constipation (“CIC”), based on IQVIA data. LINZESS is a once-daily capsule that helps relieve the abdominal pain and constipation associated with IBS-C in adults and pediatric patients 7 years of age and older. LINZESS has also been shown to relieve constipation, infrequent stools, hard stools, straining and incomplete evacuation associated with CIC in adult patients. LINZESS relieves constipation in children and adolescents aged 2 to 17 years with functional constipation.

LINZESS is not a laxative; it is the first medicine approved by the FDA in a class called GC-C agonists. LINZESS contains a peptide called linaclotide that activates the GC-C receptor in the intestine. Activation of GC-C is thought to result in increased intestinal fluid secretion and accelerated transit and a decrease in the activity of pain-sensing nerves in the intestine. The clinical relevance of the effect on pain fibers, which is based on nonclinical studies, has not been established.

In the United States, Ironwood and AbbVie co-develop and co-commercialize LINZESS for the treatment of IBS-C in adults and pediatric patients 7 years of age and older, CIC in adults and functional constipation (FC) in pediatric patients 2 years of age and older. In Europe, AbbVie markets linaclotide under the brand name CONSTELLA® for the treatment of adults with moderate to severe IBS-C. In Japan, Ironwood's partner, Astellas, markets linaclotide under the brand name LINZESS for the treatment of adults with IBS-C or CIC. Ironwood also has partnered with Grand Life Sciences (Beijing) Co. for development and commercialization of LINZESS in China, and with AbbVie for development and commercialization of linaclotide in all other territories worldwide.

LINZESS Important Safety Information

INDICATIONS AND USAGE

LINZESS® (linaclotide) is indicated for the treatment of irritable bowel syndrome with constipation (IBS-C) in adults and pediatric patients 7 years of age and older, chronic idiopathic constipation (CIC) in adults, and functional constipation (FC) in pediatric patients 2 years of age and older.

IMPORTANT SAFETY INFORMATION

WARNING:

RISK OF SERIOUS DEHYDRATION IN PEDIATRIC PATIENTS LESS THAN 2 YEARS OF AGE

LINZESS is contraindicated in patients less than 2 years of age; in nonclinical studies in neonatal mice, administration of a single, clinically relevant adult oral dose of linaclotide caused deaths due to dehydration.

Contraindications

  • LINZESS is contraindicated in patients less than 2 years of age due to the risk of serious dehydration.
  • LINZESS is contraindicated in patients with known or suspected mechanical gastrointestinal obstruction.

Warnings and Precautions

Risk of Serious Dehydration in Pediatric Patients Less Than 2 Years of Age

  • LINZESS is contraindicated in patients less than 2 years of age. In neonatal mice, linaclotide increased fluid secretion as a consequence of age-dependent elevated guanylate cyclase (GC-C) agonism, which was associated with increased mortality within the first 24 hours due to dehydration. There was no age-dependent trend in GC-C intestinal expression in a clinical study of children 2 to less than 18 years of age; however, there are insufficient data available on GC-C intestinal expression in children less than 2 years of age to assess the risk of developing diarrhea and its potentially serious consequences in these patients.

Diarrhea

  • In adults, diarrhea was the most common adverse reaction in LINZESS-treated patients in the pooled IBS-C and CIC double-blind placebo-controlled trials. The incidence of diarrhea was similar in the IBS-C and CIC populations. Severe diarrhea was reported in 2% of adult patients with IBS-C or CIC treated with LINZESS 145 mcg or 290 mcg once daily, and in <1% of adult patients with CIC treated with LINZESS 72 mcg once daily. In pediatric patients, diarrhea was also the most common adverse reaction in clinical trials of patients 7 to 17 years of age with IBS-C and 6 to 17 years of age with FC treated with LINZESS. In two double-blind trials, diarrhea was reported in 4% of pediatric patients 6 to 17 years of age with FC treated with LINZESS 72 mcg once daily, and 7% and 8% of pediatric patients 7 to 17 years of age with IBS-C treated with LINZESS 145 mcg and 290 mcg once daily, respectively. In clinical trials, severe diarrhea was reported in one pediatric patient with FC treated with LINZESS 72 mcg once daily and in one pediatric patient with IBS-C treated with LINZESS at a dose higher than the recommended 145 mcg once daily dosage for IBS-C. If severe diarrhea occurs, dosing should be suspended and the patient rehydrated.

Common Adverse Reactions (incidence ≥2% and greater than placebo)

  • In adult patients with IBS-C or CIC: diarrhea, abdominal pain, flatulence and abdominal distension.
  • In pediatric patients 7 to 17 years of age with IBS-C and 6 to 17 years of age with FC: diarrhea.

Please see full Prescribing Information including Boxed Warning: https://www.rxabbvie.com/pdf/linzess_pi.pdf

LINZESS® and CONSTELLA® are registered trademarks of Ironwood Pharmaceuticals, Inc. Any other trademarks referred to in this press release are the property of their respective owners. All rights reserved.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Investors are cautioned not to place undue reliance on these forward-looking statements, including statements about Ironwood’s ability to execute on its mission; Ironwood’s strategy, business, financial position and operations; Ironwood’s ability to drive growth and profitability and deliver sustained profits and cash flows; the commercial potential of LINZESS including its potential to return to blockbuster status for 2026; Ironwood’s financial performance and results, and guidance and expectations related thereto, including its updated full-year 2026 guidance for LINZESS U.S. net sales, total revenue and adjusted EBITDA; LINZESS prescription demand growth, LINZESS U.S. net sales, total revenue and adjusted EBITDA in 2026; the conduct and progress of the ongoing confirmatory STARS‑2 Phase 3 clinical trial, including its design and endpoints, patient recruitment, planned site expansion and activation, and timing of filing for regulatory approval; apraglutide’s potential to treat a range of rare GI diseases and to be a best-in-class therapeutic that advances the standard of care for adult patients with SBS who are dependent on PS; and the planned leadership transition, including its planned effective date. These forward-looking statements speak only as of the date of this press release, and Ironwood undertakes no obligation to update these forward-looking statements. Each forward-looking statement is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements. Applicable risks and uncertainties include those related to the effectiveness of development and commercialization efforts by us and our partners; preclinical and clinical development, manufacturing and formulation development of linaclotide, apraglutide, and our other product candidates; the risk of uncertainty relating to pricing and reimbursement policies in the U.S., which, if not favorable for our products, could hinder or prevent our products’ commercial success; the risk that clinical programs and studies, including for apraglutide, may not progress or develop as anticipated, including that studies are delayed or discontinued for any reason, such as safety, tolerability, enrollment, manufacturing, economic or other reasons; the risk that findings from our completed nonclinical studies and clinical trials may not be replicated in later trials and earlier-stage clinical trials may not be predictive of the results we may obtain in later-stage clinical trials or of the likelihood of regulatory approval; the risk that apraglutide will not be approved by the FDA or other regulatory agencies; the risk of competition or that new products may emerge that provide different or better alternatives for treatment of the conditions that our products are approved to treat; the risk that healthcare reform and other governmental and private payor initiatives may have an adverse effect upon or prevent our products’ or product candidates’ commercial success; the efficacy, safety and tolerability of linaclotide and our product candidates; the risk that the commercial and therapeutic opportunities for LINZESS, apraglutide or our other product candidates are not as we expect; decisions by regulatory and judicial authorities; the risk we may never get additional patent protection for linaclotide, apraglutide and other product candidates, that patents for linaclotide, apraglutide or other products may not provide adequate protection from competition, or that we are not able to successfully protect such patents; the risk that we are unable to manage our expenses or cash use, or are unable to commercialize our products as expected; the risk that the development of apraglutide is not successful or that any of our product candidates does not receive regulatory approval or is not successfully commercialized; outcomes in legal proceedings to protect or enforce the patents relating to our products and product candidates, including abbreviated new drug application litigation; the risk that financial and operating results may differ from our projections; developments in the intellectual property landscape; challenges from and rights of competitors or potential competitors; the risk that our planned investments do not have the anticipated effect on our company revenues; developments in accounting guidance or practice; Ironwood’s or AbbVie’s accounting practices, including reporting and settlement practices as between Ironwood and AbbVie; the risk that our indebtedness could adversely affect our financial condition or restrict our future operations; and the risks listed under the heading “Risk Factors” and elsewhere in our Annual Report on Form 10-K for the year ended December 31, 2025, and in our subsequent Securities and Exchange Commission filings.

Condensed Consolidated Balance Sheets
(In thousands)
(unaudited)
September 30, December 31,
2026 2025
Assets
Current assets:
Cash and cash equivalents $ 86,376 $ 215,456
Accounts receivable, net 132,719 46,745
Prepaid expenses and other current assets 6,898 11,977
Total current assets 225,993 274,178
Property and equipment, net 2,660 3,408
Operating lease right-of-use assets 7,980 9,340
Intangible assets, net 1,427 2,040
Deferred tax assets 48,935 103,433
Other assets 3,597 4,502
Total assets $ 290,592 $ 396,901
Liabilities and stockholders’ deficit
Current liabilities:
Accounts payable $ 3,616 $ 2,898
Accrued research and development costs 4,093 3,149
Accrued expenses and other current liabilities 23,723 33,239
Current portion of operating lease liabilities 3,301 3,252
Current portion on convertible senior notes — 199,680
Total current liabilities 34,733 242,218
Operating lease obligations, net of current portion 7,909 9,870
Revolving credit facility 325,000 385,000
Other liabilities 20,143 21,648
Total liabilities 387,785 658,736
Total stockholders’ deficit (97,193 ) (261,835 )
Total liabilities and stockholders’ deficit $ 290,592 $ 396,901
Condensed Consolidated Statements of Income
(In thousands, except per share amounts)
(unaudited)
Three Months Ended Nine Months Ended
September 30, September 30,
2026 2025 2026 2025
Total revenues $ 133,040 $ 122,060 $ 352,587 $ 248,442
Costs and expenses:
Research and development 28,352 22,468 72,713 73,273
Selling, general and administrative 11,554 21,908 34,900 62,963
Restructuring, net — 2,200 (40 ) 20,509
Total costs and expenses 39,906 46,576 107,573 156,745
Income from operations 93,134 75,484 245,014 91,697
Other income (expense):
Interest expense and other financing costs (6,198 ) (8,434 ) (22,542 ) (24,860 )
Interest and investment income 619 930 3,902 2,617
Other 41 40 125 116
Other income (expense), net (5,538 ) (7,464 ) (18,515 ) (22,127 )
Income before income taxes 87,596 68,020 226,499 69,570
Income tax expense (27,758 ) (27,940 ) (74,597 ) (43,277 )
GAAP net income $ 59,838 $ 40,080 $ 151,902 $ 26,293
GAAP net income per share—basic $ 0.36 $ 0.25 $ 0.92 $ 0.16
GAAP net income per share—diluted $ 0.36 $ 0.23 $ 0.91 $ 0.16
Reconciliation of GAAP Results to Non-GAAP Financial Measures
(In thousands, except per share amounts)
(unaudited)
A reconciliation between net income on a GAAP basis and on a non-GAAP basis is as follows:
Three Months Ended Nine Months Ended
September 30, September 30,
2026 2025 2026 2025
GAAP net income $ 59,838 $ 40,080 $ 151,902 $ 26,293
Adjustments:
Amortization of acquired intangible assets 207 207 613 613
Restructuring expenses, net — 2,200 (40 ) 20,509
Tax effect of adjustments — (554 ) 10 (5,087 )
Non-GAAP net income $ 60,045 $ 41,933 $ 152,485 $ 42,328
A reconciliation between basic net income per share on a GAAP basis and on a non-GAAP basis is as follows:
Three Months Ended Nine Months Ended
September 30, September 30,
2026 2025 2026 2025
GAAP net income per share – basic $ 0.36 $ 0.25 $ 0.92 $ 0.16
Plus: Net income per share – basic
Adjustments to GAAP net income per share (as detailed above) — 0.01 — 0.10
Non-GAAP net income per share – basic $ 0.36 $ 0.26 $ 0.92 $ 0.26
Weighted average number of common shares used to calculate net income per share – basic 164,895 162,215 164,255 161,642
A reconciliation between diluted net income per share on a GAAP basis and on a non-GAAP basis is as follows:
Three Months Ended Nine Months Ended
September 30, September 30,
2026 2025 2026 2025
GAAP net income per share – diluted $ 0.36 $ 0.23 $ 0.91 $ 0.16
Plus: Net income per share – diluted
Adjustments to GAAP net income per share (as detailed above) — 0.01 — 0.09
Non-GAAP net income per share – diluted $ 0.36 $ 0.24 $ 0.91 $ 0.25
Weighted average number of common shares used to calculate net income per share – diluted 168,177 177,764 167,530 177,057
Reconciliation of GAAP Net Income to Adjusted EBITDA
(In thousands)
(unaudited)
A reconciliation of GAAP net income to adjusted EBITDA:
Three Months Ended Nine Months Ended
September 30, September 30,
2026 2025 2026 2025
GAAP net income $ 59,838 $ 40,080 $ 151,902 $ 26,293
Adjustments:
Stock-based compensation 4,291 3,612 11,180 13,427
Restructuring expenses, net — 2,200 (40 ) 20,509
Interest expense 6,198 8,434 22,542 24,860
Interest and investment income (619 ) (930 ) (3,902 ) (2,617 )
Income tax expense 27,758 27,940 74,597 43,277
Depreciation and amortization 459 475 1,359 1,421
Adjusted EBITDA1 $ 97,925 $ 81,811 $ 257,638 $ 127,170
1Adjusted EBITDA is calculated by subtracting stock-based compensation, net restructuring expenses, net interest expense, income taxes, depreciation and amortization from GAAP net income.
U.S. LINZESS Commercial Collaboration1
Revenue/Expense Calculation
(In thousands)
(unaudited)
Three Months Ended Nine Months Ended
September 30, September 30,
2026 2025 2026 2025
LINZESS U.S. net sales as reported by AbbVie2 $ 324,919 $ 314,856 $ 879,753 $ 701,334
AbbVie & Ironwood commercial costs, expenses and other discounts3 65,739 75,826 193,353 219,618
Commercial profit on sales of LINZESS $ 259,180 $ 239,030 $ 686,400 $ 481,716
Commercial Margin4 80 % 76 % 78 % 69 %
Ironwood’s share of net profit 129,590 119,515 343,200 240,858
Reimbursement for Ironwood’s commercial expenses5 312 131 969 3,239
Ironwood’s U.S. collaborative arrangements revenue $ 129,902 $ 119,646 $ 344,169 $ 244,097
1The purpose of this table is to present calculations of Ironwood’s share of net profit generated from the sales of LINZESS in the U.S. and Ironwood’s collaboration revenue/expense; however, the table does not present the research and development expenses related to LINZESS in the U.S. that are shared equally between the parties under the collaboration agreement. Please refer to the table at the end of this press release for net profit for the U.S. LINZESS brand collaboration with AbbVie.
2LINZESS net sales are recognized using AbbVie’s revenue recognition accounting policies and reporting conventions. As a result, certain rebates and discounts are classified as LINZESS U.S. commercial costs, expenses and other discounts within Ironwood’s calculation of collaborative arrangements revenue.
3Includes certain discounts recognized and cost of goods sold incurred by AbbVie; also includes commercial costs incurred by AbbVie and Ironwood that are attributable to the cost-sharing arrangement between the parties.
4 Commercial margin is defined as commercial profit on sales of LINZESS as a percent of total LINZESS U.S. net sales.
5Year-over-year decrease reflects impact of the reduction to Ironwood’s commercial expenses and corresponding reimbursement from AbbVie due to Ironwood’s strategic reorganization announced in January 2025.
US LINZESS Full Brand Collaboration1
Revenue/Expense Calculation
(In thousands)
(unaudited)
Three Months Ended Nine Months Ended
September 30, September 30,
2026 2025 2026 2025
LINZESS U.S. net sales as reported by AbbVie2 $ 324,919 $ 314,856 $ 879,753 $ 701,334
AbbVie & Ironwood commercial costs, expenses and other discounts3 65,739 75,826 193,353 219,618
AbbVie & Ironwood R&D Expenses4 3,314 5,949 11,199 17,868
Total net profit on sales of LINZESS $ 255,866 $ 233,081 $ 675,201 $ 463,848
1 Ironwood collaborates with AbbVie on the development and commercialization of linaclotide in North America. Under the terms of the collaboration agreement, Ironwood receives 50% of the net profits and bears 50% of the net losses from the commercial sale of LINZESS in the U.S. The purpose of this table is to present calculations of the total net profit generated from the sales of LINZESS in the U.S., including the commercial costs and expenses and the research and development expenses related to LINZESS in the U.S. that are shared equally between the parties under the collaboration agreement.
2 LINZESS net sales are recognized using AbbVie’s revenue recognition accounting policies and reporting conventions. As a result, certain rebates and discounts are classified as LINZESS U.S. commercial costs, expenses and other discounts within Ironwood’s calculation of collaborative arrangements revenue.
3 Includes certain discounts recognized and cost of goods sold incurred by AbbVie; also includes commercial costs incurred by AbbVie and Ironwood that are attributable to the cost-sharing arrangement between the parties.
4Expenses related to LINZESS in the U.S. are shared equally between Ironwood and AbbVie under the collaboration agreement.

Company contact:
Chris Stamm
Vice President, Investor Relations and Communications
[email protected]

Investors:
Precision AQ
Stephanie Ascher
[email protected]

Source: Ironwood Pharmaceuticals, Inc.

Multimedia Files:

View All News

Investor Alerts

To opt-in for investor email alerts, please enter your email address in the field below and select at least one alert option. After submitting your request, you will receive an activation email to the requested email address. You must click the activation link in order to complete your subscription. You can sign up for additional alert options at any time.

At Ironwood Pharmaceuticals, Inc., we strive to treat your data with respect and will not share your information with any third party. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. If you experience any issues with this process, please contact us for further assistance.

By providing your email address below, you are providing consent to Ironwood Pharmaceuticals, Inc. to send you the requested Investor Email Alert updates.

* Required

Email Address * Mailing Lists *

News
Events & Presentations
SEC Filings
End of Day Stock Quote
Quarterly Reports
Annual Reports

Submit Submit

Email Alert Sign Up Confirmation

Ironwood Logoopen in a new window

Follow us on Linkedin Follow us on Twitter

October 28, 2026

BOSTON--(BUSINESS WIRE)-- Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), today announced it will host its third quarter 2026 investor update conference call and webcast at 8:30 a.m. Eastern Time on Thursday, November 5, 2026. Individuals interested in participating in the call should dial (833) 461-5787 (U.S.) or (585) 542-9983 (international) using conference ID number and event passcode 496523279. To access the webcast, please visit the Investors & Media section of Ironwood’s website at www.ironwoodpharma.com .

The call will be available for replay via telephone starting Thursday, November 5, 2026, at approximately 11:30 a.m. Eastern Time, running through 11:59 p.m. Eastern Time on Thursday, November 19, 2026. To listen to the replay, dial (833) 309-1852 (U.S.) or (929) 828-5978 (international) using conference ID number 496523279. Following the call, a replay of the webcast will be available on the Investors & Media section of the Company’s website at: Ironwood Pharmaceuticals, Inc. - Events & Presentations .

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals (Nasdaq: IRWD) is a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI) and rare diseases. Ironwood is advancing apraglutide, a next-generation, long-acting synthetic GLP-2 analog being developed for short bowel syndrome patients who are dependent on parenteral support. In addition, Ironwood has been a pioneer in the development of LINZESS® (linaclotide), the U.S. branded prescription market leader for the treatment of irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC). Building upon our history of innovation, we keep patients at the heart of our R&D and commercialization efforts to reduce the burden of diseases and address significant unmet needs.

Founded in 1998, Ironwood Pharmaceuticals is headquartered in Boston, Massachusetts, with a site in Basel, Switzerland.

We routinely post information that may be important to investors on our website at http://www.ironwoodpharma.com. In addition, follow us on X and on LinkedIn .

Company contact:
Chris Stamm
Vice President, Investor Relations and Communications
[email protected]

Investors:
Precision AQ
Stephanie Ascher
[email protected]

Source: Ironwood Pharmaceuticals, Inc.

Multimedia Files:

View All News

Investor Alerts

To opt-in for investor email alerts, please enter your email address in the field below and select at least one alert option. After submitting your request, you will receive an activation email to the requested email address. You must click the activation link in order to complete your subscription. You can sign up for additional alert options at any time.

At Ironwood Pharmaceuticals, Inc., we strive to treat your data with respect and will not share your information with any third party. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. If you experience any issues with this process, please contact us for further assistance.

By providing your email address below, you are providing consent to Ironwood Pharmaceuticals, Inc. to send you the requested Investor Email Alert updates.

* Required

Email Address * Mailing Lists *

News
Events & Presentations
SEC Filings
End of Day Stock Quote
Quarterly Reports
Annual Reports

Submit Submit

Email Alert Sign Up Confirmation

Ironwood Logoopen in a new window

Follow us on Linkedin Follow us on Twitter

October 16, 2026

– Tom McCourt to Retire from CEO Post After 17 Years at Ironwood and Four Decades of Distinguished Industry Leadership Bringing Transformational Medicines to Patients –

BOSTON--(BUSINESS WIRE)-- Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI) and rare diseases, today announced that its Board of Directors appointed Chief Commercial Officer Tammi Gaskins as Chief Executive Officer and a member of the Board of Directors, effective January 1, 2027. On that date Chief Executive Officer Tom McCourt will retire from his current role and will remain a member of the Board of Directors.

“The Board of Directors selected Tammi Gaskins to be Ironwood’s next CEO because she is a proven leader with a deep understanding of the business, culture and late-stage pipeline. Tammi was instrumental in driving the turnaround of LINZESS® this year, returning it to blockbuster status and growth. She is uniquely positioned to build upon the strong momentum Ironwood has delivered so far in 2026, and to lead the company through its next phase of growth,” said Julie McHugh, Chair of the Ironwood Board of Directors.

Tammi has been a leader in Ironwood’s commercial organization since joining the company in 2020 playing a critical role establishing LINZESS as the number one prescribed brand in the U.S. for the treatment of patients with irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC). She has also led commercial development efforts for apraglutide, a potential best-in-class, once-weekly GLP-2 analog in Phase 3 development for the treatment of adults with short bowel syndrome with intestinal failure (SBS-IF). Prior to joining Ironwood, Tammi held commercial leadership roles of increasing responsibilities during a 20-year tenure at AstraZeneca.

“It is an honor to be named Ironwood’s next CEO, and I would like to thank Tom and the Board of Directors for their leadership and support,” said Gaskins. “I am excited to continue working with our talented team to bring innovation to patients living with GI and rare diseases. This has been a turnaround year for Ironwood as we have worked to maximize the value of LINZESS and strengthen our balance sheet while advancing the confirmatory STARS-2 clinical trial of apraglutide in SBS-IF. With each step we are shaping Ironwood for the future, working to bring treatment advancements to patients and creating value for shareholders. I look forward to helping Ironwood continue to grow as we extend this momentum into 2027 and beyond.”

“The Board would like to thank Tom for his steady leadership over the last 17 years. From the first approval and launch of LINZESS to the acquisition of VectivBio and progress of the apraglutide program, Tom has made an indelible mark on Ironwood. We wish him well in his retirement and look forward to continuing our collaboration with him on the Board,” said McHugh.

Tom joined Ironwood as its first Chief Commercial Officer helping to shape the clinical profile of LINZESS to enable its commercial success. Building the commercial organization from the ground up, Tom and the team collaborated closely with multiple LINZESS partners over the years to grow it into a blockbuster brand. After becoming CEO in 2021, he led the effort to acquire VectivBio bringing apraglutide to Ironwood’s late-stage pipeline. Before Ironwood, Tom made significant contributions to the commercial and drug development efforts for several market-leading brands at Merck, Astra Merck, AstraZeneca, Novartis and Amgen.

“Working with Tammi closely for several years, I’ve seen first-hand the impact of her business acumen, her passion for Ironwood’s culture and, most importantly, her relentless commitment to bringing better GI medicines to patients. I have every confidence that she will be a strong successor to lead Ironwood into the future,” said McCourt. “I’m grateful for the honor of leading this company, for all of the Ironwood colleagues who shared this journey with me, and for the differences in patients’ lives we have made by working together.”

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals (Nasdaq: IRWD) is a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI) and rare diseases. Ironwood is advancing apraglutide, a next-generation, long-acting synthetic GLP-2 analog being developed for short bowel syndrome patients who are dependent on parenteral support. In addition, Ironwood has been a pioneer in the development of LINZESS® (linaclotide), the U.S. branded prescription market leader for the treatment of irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC). Building upon our history of innovation, we keep patients at the heart of our R&D and commercialization efforts to reduce the burden of diseases and address significant unmet needs.

Founded in 1998, Ironwood Pharmaceuticals is headquartered in Boston, Massachusetts, with a site in Basel, Switzerland.

We routinely post information that may be important to investors on our website at www.ironwoodpharma.com . In addition, follow us on X and on LinkedIn .

About LINZESS (Linaclotide)

LINZESS® is the #1 prescribed brand in the U.S. for the treatment of patients with irritable bowel syndrome with constipation (“IBS-C”) or chronic idiopathic constipation (“CIC”), based on IQVIA data. LINZESS is a once-daily capsule that helps relieve the abdominal pain and constipation associated with IBS-C in adults and pediatric patients 7 years of age and older. LINZESS has also been shown to relieve constipation, infrequent stools, hard stools, straining and incomplete evacuation associated with CIC in adult patients. LINZESS relieves constipation in children and adolescents aged 2 to 17 years with functional constipation.

LINZESS is not a laxative; it is the first medicine approved by the FDA in a class called GC-C agonists. LINZESS contains a peptide called linaclotide that activates the GC-C receptor in the intestine. Activation of GC-C is thought to result in increased intestinal fluid secretion and accelerated transit and a decrease in the activity of pain-sensing nerves in the intestine. The clinical relevance of the effect on pain fibers, which is based on nonclinical studies, has not been established.

In the United States, Ironwood and AbbVie co-develop and co-commercialize LINZESS for the treatment of IBS-C in adults and pediatric patients 7 years of age and older, CIC in adults and functional constipation (FC) in pediatric patients 2 years of age and older. In Europe, AbbVie markets linaclotide under the brand name CONSTELLA® for the treatment of adults with moderate to severe IBS-C. In Japan, Ironwood’s partner, Astellas, markets linaclotide under the brand name LINZESS for the treatment of adults with IBS-C or CIC. Ironwood also has partnered with Grand Life Sciences for development and commercialization of LINZESS in China, and with AbbVie for development and commercialization of linaclotide in all other territories worldwide.

LINZESS Important Safety Information

INDICATIONS AND USAGE

LINZESS® (linaclotide) is indicated for the treatment of irritable bowel syndrome with constipation (IBS-C) in adults and pediatric patients 7 years of age and older, chronic idiopathic constipation (CIC) in adults, and functional constipation (FC) in pediatric patients 2 years of age and older.

IMPORTANT SAFETY INFORMATION

WARNING:

RISK OF SERIOUS DEHYDRATION IN PEDIATRIC PATIENTS LESS THAN 2 YEARS OF AGE

LINZESS is contraindicated in patients less than 2 years of age; in nonclinical studies in neonatal mice, administration of a single, clinically relevant adult oral dose of linaclotide caused deaths due to dehydration.

Contraindications

  • LINZESS is contraindicated in patients less than 2 years of age due to the risk of serious dehydration.
  • LINZESS is contraindicated in patients with known or suspected mechanical gastrointestinal obstruction.

Warnings and Precautions

Risk of Serious Dehydration in Pediatric Patients Less Than 2 Years of Age

  • LINZESS is contraindicated in patients less than 2 years of age. In neonatal mice, linaclotide increased fluid secretion as a consequence of age-dependent elevated guanylate cyclase (GC-C) agonism, which was associated with increased mortality within the first 24 hours due to dehydration. There was no age-dependent trend in GC-C intestinal expression in a clinical study of children 2 to less than 18 years of age; however, there are insufficient data available on GC-C intestinal expression in children less than 2 years of age to assess the risk of developing diarrhea and its potentially serious consequences in these patients.

Diarrhea

  • In adults, diarrhea was the most common adverse reaction in LINZESS-treated patients in the pooled IBS-C and CIC double-blind placebo-controlled trials. The incidence of diarrhea was similar in the IBS-C and CIC populations. Severe diarrhea was reported in 2% of adult patients with IBS-C or CIC treated with LINZESS 145 mcg or 290 mcg once daily, and in <1% of adult patients with CIC treated with LINZESS 72 mcg once daily. In pediatric patients, diarrhea was also the most common adverse reaction in clinical trials of patients 7 to 17 years of age with IBS-C and 6 to 17 years of age with FC treated with LINZESS. In two double-blind trials, diarrhea was reported in 4% of pediatric patients 6 to 17 years of age with FC treated with LINZESS 72 mcg once daily, and 7% and 8% of pediatric patients 7 to 17 years of age with IBS-C treated with LINZESS 145 mcg and 290 mcg once daily, respectively. In clinical trials, severe diarrhea was reported in one pediatric patient with FC treated with LINZESS 72 mcg once daily and in one pediatric patient with IBS-C treated with LINZESS at a dose higher than the recommended 145 mcg once daily dosage for IBS-C. If severe diarrhea occurs, dosing should be suspended and the patient rehydrated.

Common Adverse Reactions (incidence ≥2% and greater than placebo)

  • In adult patients with IBS-C or CIC: diarrhea, abdominal pain, flatulence and abdominal distension.
  • In pediatric patients 7 to 17 years of age with IBS-C and 6 to 17 years of age with FC: diarrhea.

Please see full Prescribing Information including Boxed Warning:

https://www.rxabbvie.com/pdf/linzess_pi.pdf

LINZESS® and CONSTELLA® are registered trademarks of Ironwood Pharmaceuticals, Inc. Any other trademarks referred to in this press release are the property of their respective owners. All rights reserved.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Investors are cautioned not to place undue reliance on these forward-looking statements, including statements about Ironwood’s ability to execute on its mission; Ironwood’s strategy, business, financial position and operations; Ironwood’s ability to drive growth and profitability; the commercial potential of LINZESS; the leadership transition, including its planned effective date and the anticipated benefits of the transition; and the potential of apraglutide to become a best-in-class treatment for adults with SBS-IF. These forward-looking statements speak only as of the date of this press release, and Ironwood undertakes no obligation to update these forward-looking statements. Each forward-looking statement is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements. Applicable risks and uncertainties include those related to the effectiveness of development and commercialization efforts by us and our partners; preclinical and clinical development, manufacturing and formulation development of linaclotide, apraglutide, and our other product candidates; the risk of uncertainty relating to pricing and reimbursement policies in the U.S., which, if not favorable for our products, could hinder or prevent our products’ commercial success; the risk that clinical programs and studies, including for apraglutide, may not progress or develop as anticipated, including that studies are delayed or discontinued for any reason, such as safety, tolerability, enrollment, manufacturing, economic or other reasons; the risk that findings from our completed nonclinical studies and clinical trials may not be replicated in later trials and earlier-stage clinical trials may not be predictive of the results we may obtain in later-stage clinical trials or of the likelihood of regulatory approval; the risk that apraglutide will not be approved by the FDA or other regulatory agencies; the risk of competition or that new products may emerge that provide different or better alternatives for treatment of the conditions that our products are approved to treat; the risk that healthcare reform and other governmental and private payor initiatives may have an adverse effect upon or prevent our products’ or product candidates’ commercial success; the efficacy, safety and tolerability of linaclotide and our product candidates; the risk that the commercial and therapeutic opportunities for LINZESS, apraglutide or our other product candidates are not as we expect; decisions by regulatory and judicial authorities; the risk we may never get additional patent protection for linaclotide, apraglutide and other product candidates, that patents for linaclotide, apraglutide or other products may not provide adequate protection from competition, or that we are not able to successfully protect such patents; the risk that we are unable to manage our expenses or cash use, or are unable to commercialize our products as expected; the risk that the development of apraglutide is not successful or that any of our product candidates does not receive regulatory approval or is not successfully commercialized; outcomes in legal proceedings to protect or enforce the patents relating to our products and product candidates, including abbreviated new drug application litigation; the risk that financial and operating results may differ from our projections; developments in the intellectual property landscape; challenges from and rights of competitors or potential competitors; the risk that our planned investments do not have the anticipated effect on our company revenues; developments in accounting guidance or practice; Ironwood’s or AbbVie’s accounting practices, including reporting and settlement practices as between Ironwood and AbbVie; the risk that our indebtedness could adversely affect our financial condition or restrict our future operations; and the risks listed under the heading “Risk Factors” and elsewhere in our Annual Report on Form 10-K for the year ended December 31, 2025, and in our subsequent Securities and Exchange Commission filings.

Investors and Media:
Chris Stamm
Vice President, Investor Relations and Communications
[email protected]

Investors:
Precision AQ
Stephanie Ascher
[email protected]

Source: Ironwood Pharmaceuticals, Inc.

Multimedia Files:

View All News

Investor Alerts

To opt-in for investor email alerts, please enter your email address in the field below and select at least one alert option. After submitting your request, you will receive an activation email to the requested email address. You must click the activation link in order to complete your subscription. You can sign up for additional alert options at any time.

At Ironwood Pharmaceuticals, Inc., we strive to treat your data with respect and will not share your information with any third party. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. If you experience any issues with this process, please contact us for further assistance.

By providing your email address below, you are providing consent to Ironwood Pharmaceuticals, Inc. to send you the requested Investor Email Alert updates.

* Required

Email Address * Mailing Lists *

News
Events & Presentations
SEC Filings
End of Day Stock Quote
Quarterly Reports
Annual Reports

Submit Submit

Email Alert Sign Up Confirmation

Ironwood Logoopen in a new window

Follow us on Linkedin Follow us on Twitter

Prompts

Ironwood Pharmaceuticals, Inc. (ticker IRWD), listed in United States.

ETFs Holding Ironwood Pharmaceuticals, Inc.

ETF Weight in ETF Shares Market value As of
DSMC 0.59% 180,929 $ 761.711K Jun 30, 2026
FSML 0.54% 161,157 $ 678.471K Jun 30, 2026
SQLV 0.27% 18,553 $ 78.108K Jun 30, 2026
SEIS 0.13% 179,443 $ 755.455K Jun 30, 2026
VFVA 0.12% 277,720 $ 1.18M Aug 31, 2026
VFMO 0.11% 514,755 $ 2.188M Aug 31, 2026
FSEG 0.07% 968 $ 4,075.28 Jun 30, 2026
FESM 0.05% 740,102 $ 3.116M Jun 30, 2026
FSEV 0.05% 845 $ 3,557.45 Jun 30, 2026
RESM 0.02% 185 $ 778.85 Jun 30, 2026
DFAS 0.02% 1,148,078 $ 5.568M Nov 12, 2026
DFAC 0.00% 439,643 $ 2.132M Nov 12, 2026
DFSU 0.00% 8,700 $ 42.195K Nov 12, 2026
DFUS 0.00% 47,075 $ 228.314K Nov 12, 2026
DCOR 0.00% 77,796 $ 377.311K Nov 12, 2026
DFAU 0.00% 11,941 $ 57.914K Nov 12, 2026